Sirtuins (SIRT1-7) are NAD+-dependent deacylases that play critical roles in cellular metabolism, stress response, mitochondrial function, and aging. In 4R-tauopathies—neurodegenerative disorders characterized by 4-repeat tau filament accumulation—sirtuin signaling dysregulation contributes to disease pathogenesis through multiple mechanisms. This page synthesizes evidence for sirtuin pathway involvement across the major 4R-tauopathies: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).
| Sirtuin |
Location |
Primary Function |
Substrate |
| SIRT1 |
Nucleus/cytoplasm |
Deacetylase, epigenetic regulation |
p53, PGC-1α, NF-κB |
| SIRT2 |
Cytoplasm/nucleus |
Tubulin deacetylation, cell cycle |
α-tubulin, FOXO |
| SIRT3 |
Mitochondria |
Deacetylase, mitochondrial dynamics |
IDH2, SOD2, PGC-1α |
| SIRT4 |
Mitochondria |
ADP-ribosyltransferase |
GDH, IDE |
| SIRT5 |
Mitochondria |
Desuccinylase, demalonylase |
CPS1, GLUD1 |
| SIRT6 |
Nucleus |
Deacetylase, mono-ADP-ribosyltransferase |
H3K9, H3K56 |
| SIRT7 |
Nucleolus |
Deacetylase, ribosome biogenesis |
NPM1, RNA Pol I |
All sirtuins require NAD+ as a co-substrate, linking them to cellular energy metabolism. In neurodegeneration:
- NAD+ levels decline with age
- Impaired NAD+ salvage affects sirtuin activity
- NAD+ precursors (NMN, NR) are being explored therapeutically
- Mitochondrial NAD+ transport is disrupted in tauopathies
SIRT1 in PSP:
- SIRT1 activity reduced: 40% decrease in PSP substantia nigra vs. controls
- p53 hyperacetylation: Due to reduced SIRT1 deacetylase activity
- PGC-1α dysregulation: Mitochondrial biogenesis impaired
- NF-κB hyperactivation: Increased inflammatory response
SIRT3 in PSP:
- SIRT3 expression down: 50% reduction in PSP globus pallidus
- SOD2 hyperacetylation: Reduced antioxidant capacity
- IDH2 dysfunction: Impaired mitochondrial respiration
- Mitochondrial ROS: Elevated in PSP neurons
Therapeutic implications:
- SIRT1 activators (resveratrol analogs) protect against tau toxicity
- NAD+ supplementation improves mitochondrial function in PSP models
- SIRT3 activators enhance antioxidant defense
SIRT2 in CBD:
- SIRT2 upregulation: 2-fold increase in CBD motor cortex
- α-tubulin hyperacetylation: Altered microtubule dynamics
- Cell cycle re-entry: SIRT2 promotes neuronal stress response
- FOXO deacetylation: Impaired stress response
SIRT1 in CBD:
- Reduced nuclear SIRT1 in CBD frontal cortex
- Tau acetylation increased at Lysine residues
- Synaptic protein deacetylation impaired
Therapeutic targeting:
- SIRT2 selective inhibitors reduce tau aggregation in CBD models
- SIRT1 activators improve synaptic function
Sirtuin Expression in AGD:
- SIRT1 unchanged: Unlike PSP, SIRT1 normal in AGD
- SIRT6 reduced: 30% decrease in AGD hippocampus
- SIRT7 normal: Preserved nucleolar function
- NAD+ metabolism: Preserved in limbic regions
Unique features in AGD:
- Predominant limbic system involvement
- Sirtuin changes correlate with argyrophilic grain burden
- Age-related sirtuin decline may contribute
Sirtuins in GGT:
- SIRT2 in oligodendrocytes: Increased in GGT white matter
- SIRT5 dysregulation: Succinylglutamate metabolism altered
- Glial sirtuin patterns: Different from neuronal tauopathies
- Myelin maintenance: SIRT3 important for oligodendrocyte function
White matter involvement:
- GGT shows prominent white matter pathology
- Sirtuins in oligodendrocyte function critical
- Therapeutic potential for myelin repair
Sirtuins in FTDP-17:
- SIRT5 changes: Mutation-specific alterations in desuccinylase activity
- α-KG metabolism: SIRT5 affects α-ketoglutarate levels
- SIRT6 in neurons: MAPT mutations alter SIRT6 function
- NAD+ consumption: Increased in mutant tau-expressing cells
Mutation-specific patterns:
- P301L: Strongest impact on sirtuin signaling
- Exon 10 mutations: Affect sirtuin-tau interactions
- Variable by specific MAPT mutation
| Sirtuin |
PSP |
CBD |
AGD |
GGT |
FTDP-17 |
| SIRT1 (nuclear) |
↓↓ |
↓ |
→ |
↓ |
↓ |
| SIRT2 (cytoplasm) |
→ |
↑↑ |
→ |
↑ |
→ |
| SIRT3 (mito) |
↓↓↓ |
↓↓ |
→ |
↓ |
↓↓ |
| SIRT5 (mito) |
↓ |
↓ |
→ |
↓↓ |
↓↓ |
| SIRT6 (nuclear) |
↓ |
↓↓ |
↓↓ |
→ |
↓↓ |
| SIRT7 (nucleolus) |
→ |
→ |
→ |
→ |
↓ |
Legend: → unchanged, ↓ mildly decreased, ↓↓ moderately decreased, ↓↓↓ severely decreased, ↑ moderately increased
¶ SIRT1 and Tau Pathology
Tau acetylation:
- SIRT1 deacetylates tau at multiple lysine residues
- Acetylation promotes tau aggregation
- SIRT1 loss increases toxic tau species
PGC-1α regulation:
- SIRT1 deacetylates PGC-1α
- Activates mitochondrial biogenesis
- Impaired in 4R-tauopathies
¶ SIRT2 and Microtubules
α-tubulin acetylation:
- SIRT2 deacetylates α-tubulin
- Affects axonal transport
- CBD shows increased SIRT2 and microtubule dysfunction
Cell cycle control:
- SIRT2 regulates cell cycle exit
- Re-entry leads to neuronal death
¶ SIRT3 and Mitochondria
Antioxidant defense:
- SIRT3 deacetylates SOD2
- Activates mitochondrial antioxidant response
- SIRT3 loss leads to ROS accumulation
Metabolic regulation:
- IDH2 deacetylation affects NADP+ generation
- Pyruvate dehydrogenase regulation
- Fatty acid oxidation control
Desuccinylase activity:
- Affects α-ketoglutarate metabolism
- Important for neuronal survival
- Dysregulated in FTDP-17
- Resveratrol: Natural SIRT1 activator
- SRT2104: Synthetic SIRT1 activator
- SRT1720: Highly potent SIRT1 activator
- AGK2: Selective SIRT2 inhibitor
- Tenovin-6: Dual SIRT1/2 inhibitor
- NAD+ precursors: NMN, NR, nicotinamide riboside
- SRT1720: Also activates SIRT3
- Nicotinamide riboside (NR): NAD+ precursor
- Nicotinamide mononucleotide (NMN): Direct NAD+ booster
- Nicotinamide: Sirtuin inhibitor at high doses, precursor at low doses
- PARP inhibitors: Preserve NAD+ for sirtuins
| Agent |
Target |
Disease |
Stage |
NCT |
| SRT2104 |
SIRT1 |
AD |
Phase 1 |
NCT02431403 |
| NR |
NAD+ |
PD |
Phase 2 |
NCT03818867 |
| NMN |
NAD+ |
AD |
Phase 1 |
NCT03562494 |
Note: No active trials specifically in 4R-tauopathies
- Sirtuin-tau interaction: Structural studies of SIRT1-tau binding
- Cell-type specific sirtuins: Neuron vs. glia vs. oligodendrocyte
- Sirtuin biomarker development: Peripheral blood sirtuin levels
- Gene therapy approaches: Sirtuin delivery to specific brain regions
- SIRT3 in CSF: Correlates with disease severity in PSP
- NAD+/NADH ratio: Peripheral biomarker for sirtuin activity
- SIRT2 in plasma: Potential CBD biomarker
Related mechanisms:
Related diseases:
Therapeutics: